

Overview

- The Australian Government's Expert Review of Medicines and Medical Devices Regulation (MMDR) -Implementation
- Recently Published Guidance
- Other activities

Summary of MMDR Implementation

Summary of wilder implementation					
Recommendation	Legislation/Guidance Published	Implementation			
Expedited review process for certain 'novel' devices	Legislation January 2018 Guidance January 2018	2 January 2018	√		
Designation of Australian conformity assessment bodies	Legislation March 2018 Guidance September 2018	20 March 2018	√		
Use of approvals from comparable overseas regulators	Legislation September 2018 Guidance August 2018	13 September 2018	√		
Continued alignment with the European Union	Staged Approach to Harmonise with MDR 2017/745 and IVDR 2017/746	First Changes Commence 1 December 2018			
Review of Low Risk Products in the ARTG	Legislation to exempt Tampons/Menstrual Cups (Other reviews ongoing)	1 July 2018			
Strengthening of post market monitoring	Guidance to encourage consumer reporting eg Consumer Story BIA-ALCL (Other guidance in development)	7 September 2018			

Comparable overseas regulators

- Approvals by comparable regulators (or their designated bodies) will be accepted as supporting evidence for ARTG* applications
- Comparable overseas regulators will initially be:
 - European Union through notified body certification (in place since 2002)
 - USA
 - Canada
 - Japan
- MDSAP certification is required as QMS evidence in many cases

^{*}Australian Register of Therapeutic Goods

Alignment with Europe – First changes

- Up-classification of surgical mesh
- Patient implant cards / patient information leaflets

	Up-classification	Device info leaflet	Patient implant card		
Urogynaecological mesh					
New devices	1 Dec 2018	1 Dec 2018	1 Dec 2018		
Existing devices	1 Dec 2020	1 Dec 2019	1 Dec 2019		
Surgical mesh					
New devices	1 Dec 2018	1 Dec 2018	1 Dec 2020		
Existing devices	1 Dec 2021	1 Dec 2021	1 Dec 2021		
Implantable devices (other than those exempted)					
New devices	NA	1 Dec 2018	1 Dec 2020		
Existing devices	NA	1 Dec 2021	1 Dec 2021		

Strengthening of post market monitoring

- From August 2018, IMDRF terminology and codes have been integrated into TGA databases and are being used by TGA in its assessment of medical device adverse event reports.
- Redesign of analytics tools for signal detection and risk frameworks for triaging adverse events for investigation
- Web-based adverse event reporting forms being redesigned to address needs of healthcare providers and consumers
- Increasing capacity for targeted post-market reviews
- Greater use of expert panels for significant post-market issues, recent examples:
 - Breast Implant Associated Anaplastic Large Cell Lymphoma
 - Critical care ventilators



Recent Guidance

Consumer story: Georgia and breast implant associated cancer

- 7 September 2018
- Learn how to spot the warning signs for breast implant associated cancer in our new consumer story

Comparable overseas regulators for medical device applications

- 20 August 2018
- Use of market authorisation evidence from comparable overseas regulators for medical devices

<u>Application requirements for medical devices - preliminary assessment</u>

- 20 August 2018
- Applications for the inclusion of medical devices in the ARTG must meet certain requirements in order to pass preliminary assessment

Recent Guidance

Electronic Instructions for Use - eIFU

- 15 August 2018
- New guidance on electronic instructions for use for medical devices

Guidance on the regulation of tampons in Australia

- 2 August 2018
- Updated to reflect the exemption of tampons from the regulatory requirement to include them on the ARTG

Other key activities

- Personalised Medical Devices
 - 2nd Stakeholder Workshop 4 July 2018
 - Consultation to be conducted on the adoption of IMDRF definitions
- Software as a Medical Device & Cyber Security for Medical Devices
 - TGA is working with the Commonwealth Scientific and Industrial Research Organisation (CSIRO)
 - Webinar on Cyber Security 14 September 2018
 - Consultation to be conducted on the adoption of IMDRF SaMD risk framework
- Companion Diagnostics
 - Preparing to conduct a public consultation on regulatory changes

Thank you